Trial record 3 of 27 for:    LY2216684

A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01389752
First received: July 6, 2011
Last updated: September 23, 2011
Last verified: September 2011
  Purpose

The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.

The study will evaluate the effect of charcoal on the absorption of LY2216684. Side effects will be documented. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last dose. Screening is required within 30 days prior to the start of the study.


Condition Intervention Phase
Depressive Disorder, Major
Drug: LY2216684
Drug: Activated Charcoal
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Activated Charcoal on the Pharmacokinetics of LY2216684 in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Pharmacokinetics: area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) of LY2216684 [ Time Frame: Predose, up to 72 hours after administration of study drug ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum observed plasma concentration (Cmax) of LY2216684 [ Time Frame: Predose, up to 72 hours after administration of study drug ] [ Designated as safety issue: No ]
  • Pharmacokinetics: time to maximum plasma concentration (tmax) of LY2216684 [ Time Frame: Predose, up to 72 hours after administration of study drug ] [ Designated as safety issue: No ]

Estimated Enrollment: 22
Study Start Date: July 2011
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY2216684 without Charcoal First, then with Charcoal
Period 1: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 without Activated Charcoal. Periods will be separated by a minimum of 7 days. Period 2: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 with single oral dose of 1 gm/kg of Activated Charcoal administered orally.
Drug: LY2216684
Administered orally
Drug: Activated Charcoal
Administered orally
Experimental: LY2216684 with Charcoal First, then without Charcoal
Period 1: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 with single oral dose of 1 gm/kg of Activated Charcoal administered orally. Periods will be separated by a minimum of 7 days. Period 2: Single 18mg (2 x 9 mg tablets) oral dose of LY2216684 administered on Day 1 without Activated Charcoal.
Drug: LY2216684
Administered orally
Drug: Activated Charcoal
Administered orally

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Are overtly healthy, as determined by medical history and physical examination

    - Male subjects: Agree to use a reliable method of birth control during the study and for 1 month following the last dose of the study drug

    - Female subjects: Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone [FSH] >40 mIU/mL)

  • Have a body weight >50 kg
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Have given written informed consent approved by Lilly and the institutional review board (IRB) governing the site
  • Have normal blood pressure (BP) and pulse rate (sitting position)

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product other than the investigational product used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to LY2216684, related compounds, or any components of the formulation
  • Are persons who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to Screening
  • Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation
  • Have a documented or suspected history of glaucoma
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Show evidence of hepatitis C and/or positive hepatitis C antibody
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen
  • Are women who are lactating
  • Intend to use over-the-counter or prescription medication within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor. Exceptions include influenza vaccinations, the use of topical medication (provided there is no evidence of chronic dosing with the risk of systemic exposure), occasional use of acetaminophen/paracetamol/ibuprofen, hormone replacement therapy including thyroid replacement (stable dose for at least 1 month), and stable doses (at least 1 month) of oral contraceptive therapy
  • Have donated blood of more than 500 mL within the last month
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females), or are unwilling to stop alcohol consumption from 48 hours prior to dosing in each period until discharge in each period (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Consume 5 or more cups of coffee (or other beverages or foods of comparable caffeine content) per day, on a habitual basis, or are unwilling to stop caffeine consumption from 48 hours prior to dosing in each period until discharge in each period
  • Subjects unwilling to adhere to the smoking restrictions of the Clinical Research Unit (CRU) while a resident of the CRU.
  • Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment or are unwilling to avoid them during the study
  • Subjects determined to be unsuitable by the investigator for any reason
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01389752

Locations
United States, Texas
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01389752     History of Changes
Other Study ID Numbers: 12612, H9P-EW-LNCU
Study First Received: July 6, 2011
Last Updated: September 23, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Charcoal
Antidotes
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 24, 2014